Juniper Biologics acquires cell-mediated gene therapy TG-C LD

By The Science Advisory Board staff writers

April 19, 2022 -- Juniper Biologics has acquired the licensing rights to develop and commercialize TissueGene-C low dose (TG-C LD), a cell therapy-based treatment for knee osteoarthritis.

Kolon Life Science and Juniper Biologics signed a $600 million licensing deal under which Juniper will be responsible for developing and commercializing TG-C LD to medical professionals and hospitals within Asia Pacific, the Middle East, and Africa. Kolon will support the development and supply of TG-C LD.

TG-C LD is a cell-mediated gene therapy that targets knee osteoarthritis through a single intra-articular injection. TG-C-LD completed phase II clinical trial in the U.S. with promising initial data, according to a press release from Juniper Biologics.

Phase III clinical trials were designed to show the delay of disease progression to achieve a disease-modifying osteoarthritis drug designation.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter